Table 5.
Treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs) in different NLR groups
| Group | TRAEs | TRAEs grade ≥3 | irAEs |
|---|---|---|---|
| bNLR | |||
| ≤2.7 | 17 (77.3) | 4 (18.2) | 7 (31.2) |
| >2.7 | 23 (74.2) | 8 (25.8) | 7 (22.6) |
| P-value | 0.797 | 0.740 | 0.452 |
| dNLR | |||
| ≤1.5 | 28 (87.9) | 7 (21.2) | 10 (30.3) |
| >1.5 | 11 (57.9) | 5 (26.3) | 4 (21.1) |
| P-value | 0.031* | 0.471 | 0.534 |
| Combination of bNLR and dNLR | |||
| ≤2.7, ≤1.5 | 12 (92.3) | 3 (23.1) | 5 (38.5) |
| >2.7, ≤1.5 | 15 (75.0) | 4 (20.0) | 5 (25.0) |
| ≤2.7, >1.5 | 6 (75.0) | 1 (12.5) | 2 (25.0) |
| >2.7, >1.5 | 7 (63.6) | 4 (36.4) | 2 (18.2) |
| P-value | 0.422 | 0.686 | 0.757 |
The values are presented as the number of cases following the percentage in parentheses.
TRAEs, treatment-related adverse events; irAEs, immune-related adverse events; bNLR, baseline blood neutrophil-to-lymphocyte ratio; dNLR, dynamic change of blood NLR.
*
P < 0.05.